Table 4. Number of subjects (%) who experienced treatment-emergent AEs following administration of nemonoxacin with or without ferrous sulfate/calcium carbonate. n=12.
| AE | Treatmentsa |
||
|---|---|---|---|
| E | F | Gb | |
| Subjects experiencing AE(s) | 4 (33.3%) | 2 (16.7%) | 3 (23.1%) |
| AEs related to study drug | 2 (16.7%) | 1 (8.3%) | 2 (15.4%) |
| Investigations | |||
| ALT increased | 1 (8.3%) | 0 | 0 |
| Blood uric acid increased | 2 (16.7%) | 1 (8.3%) | 2 (15.4%) |
| AEs related to study drug | 3 (25%) | 1 (8.3%) | 1 (7.7%) |
| Gastrointestinal disorders | |||
| Toothache | 1 (8.3%) | 0 | 0 |
| General disorders and administration site conditions | |||
| Pyrexia | 1 (8.3%) | 0 | 0 |
| Investigations | |||
| ALT increased | 1 (8.3%) | 1 (8.3%) | 0 |
| CPK increased | 1 (8.3%) | 0 | 1 (7.7%) |
| WBC count decreased | 1 (8.3%) | 0 | 0 |
| WBC count increased | 1 (8.3%) | ||
| Musculoskeletal and connective tissue disorders | |||
| Arthritis bacterial | 1 (8.3%) | 0 | 0 |
| Arthralgia | 1 (8.3%) | 0 | 0 |
a E, nemonoxacin was administered alone; F, nemonoxacin was administered at the same time as ferrous sulfate; G, nemonoxacin was administered at the same time as calcium carbonate. n=13.
b CPK, blood creatine phosphokinase; ALT, alanine aminotransferase; WBC, white blood cell.